Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-616 + Low-dose Cytarabine in AML/MDS
NCT01795924Phase 2Terminated
- Sponsor
- Biosuccess Biotech Co., Ltd.
- Start
- Jan 2013
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PD-616 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Biosuccess Biotech Co., Ltd. Primary endpoints: Dose-Limiting Toxicities at 28 days and Overall Response Rate at 1 year. Started Jan 2013; status: terminated.
02
Drugs
PD-616
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01795924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01795924.